Regulus Hit As Partner Sanofi Pulls Plug On Kidney Drug Study
Rare Kidney Diseases Proving Difficult For Both Companies
Sanofi has abandoned its study of lademirsen in Alport disease, but has not given up on the drug just yet as another indication remains in play.
You may also be interested in...
The French drugmaker has halted a pivotal trial of venglustat in autosomal dominant polycystic kidney disease, a few months after the drug failed as a treatment for Parkinson’s disease. Sanofi will go back to focusing on the therapy's potential in lysosomal storage diseases.
Its mRNA-based RSV vaccine challenger has a more convenient administration than GSK and Pfizer’s frontrunners, but may not compete on durability of protection.
Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.